Ultragenyx Pharmaceutical Inc. (RARE)
RARE Stock Price Chart
Explore Ultragenyx Pharmaceutical Inc. interactive price chart. Choose custom timeframes to analyze RARE price movements and trends.
RARE Company Profile
Discover essential business fundamentals and corporate details for Ultragenyx Pharmaceutical Inc. (RARE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2014
Employees
1.29k
Website
https://www.ultragenyx.comCEO
Emil D. Kakkis
Description
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
RARE Financial Timeline
Browse a chronological timeline of Ultragenyx Pharmaceutical Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$1.27, while revenue estimate is $180.61m.
Earnings released on 5 May 2026
EPS came in at -$1.84 falling short of the estimated -$1.49 by -23.67%, while revenue for the quarter reached $136.00m , missing expectations by -14.03%.
Earnings released on 12 Feb 2026
EPS came in at -$1.29 falling short of the estimated -$1.20 by -7.50%, while revenue for the quarter reached $207.00m , beating expectations by +4.23%.
Earnings released on 4 Nov 2025
EPS came in at -$1.81 falling short of the estimated -$1.23 by -47.15%, while revenue for the quarter reached $159.93m , missing expectations by -19.94%.
Earnings released on 5 Aug 2025
EPS came in at -$1.17 surpassing the estimated -$1.27 by +7.87%, while revenue for the quarter reached $166.50m , beating expectations by +0.33%.
Earnings released on 6 May 2025
EPS came in at -$1.57 falling short of the estimated -$1.54 by -1.95%, while revenue for the quarter reached $139.29m , missing expectations by -14.23%.
Earnings released on 13 Feb 2025
EPS came in at -$1.39 falling short of the estimated -$1.32 by -5.30%, while revenue for the quarter reached $164.88m , beating expectations by +3.89%.
Earnings released on 5 Nov 2024
EPS came in at -$1.40 surpassing the estimated -$1.45 by +3.45%, while revenue for the quarter reached $139.49m , missing expectations by -4.81%.
Earnings released on 1 Aug 2024
EPS came in at -$1.52 surpassing the estimated -$1.64 by +7.32%, while revenue for the quarter reached $147.03m , beating expectations by +19.36%.
Earnings released on 2 May 2024
EPS came in at -$2.03 falling short of the estimated -$1.72 by -18.02%, while revenue for the quarter reached $108.83m , missing expectations by -6.19%.
Earnings released on 15 Feb 2024
EPS came in at -$1.52 surpassing the estimated -$1.65 by +7.88%, while revenue for the quarter reached $127.39m , beating expectations by +6.71%.
Earnings released on 2 Nov 2023
EPS came in at -$2.23 falling short of the estimated -$2.08 by -7.21%, while revenue for the quarter reached $98.05m , missing expectations by -10.88%.
Earnings released on 3 Aug 2023
EPS came in at -$2.25 falling short of the estimated -$2.11 by -6.64%, while revenue for the quarter reached $108.31m , beating expectations by +3.35%.
Earnings released on 4 May 2023
EPS came in at -$2.33 falling short of the estimated -$1.97 by -18.27%, while revenue for the quarter reached $100.50m , missing expectations by -4.01%.
Earnings released on 16 Feb 2023
EPS came in at -$2.16 falling short of the estimated -$2.03 by -6.40%, while revenue for the quarter reached $103.35m , missing expectations by -1.68%.
Earnings released on 2 Nov 2022
EPS came in at -$2.43 falling short of the estimated -$2.29 by -6.11%, while revenue for the quarter reached $90.70m , missing expectations by -5.97%.
Earnings released on 28 Jul 2022
EPS came in at -$2.26 falling short of the estimated -$1.72 by -31.40%, while revenue for the quarter reached $89.34m , beating expectations by +1.77%.
Earnings released on 5 May 2022
EPS came in at -$2.19 falling short of the estimated -$1.76 by -24.43%, while revenue for the quarter reached $79.94m , missing expectations by -4.44%.
Earnings released on 10 Feb 2022
EPS came in at -$1.79 falling short of the estimated -$1.32 by -35.61%, while revenue for the quarter reached $83.39m , missing expectations by -0.49%.
Earnings released on 2 Nov 2021
EPS came in at -$1.08 surpassing the estimated -$1.43 by +24.48%, while revenue for the quarter reached $81.65m , missing expectations by -0.89%.
Earnings released on 2 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$1.28 by -13.28%, while revenue for the quarter reached $86.98m , meeting expectations.
RARE Stock Performance
Access detailed RARE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
